Adenosine antagonists reverse the cataleptic effects of haloperidol: Implications for the treatment of Parkinson's disease

Pharmacology Biochemistry and Behavior

Volumn 92, Issue 3, 2009, Pages 521-527

  Trevitt, Jennifer ^a   Vallance, Christopher ^a   Harris, Allison ^a   Goode, Tamara ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

A1; A2A; Adenosine; Basal ganglia; Caffeine; CPT; Dopamine; Parkinson's disease; Rat; SCH23390

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 CYCLOPENTYL 1,3 DIMETHLY XANTHINE; ADENOSINE A1 RECEPTOR ANTAGONIST; CAFFEINE; HALOPERIDOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG EFFECT; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; CAFFEINE; CATALEPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; PARKINSON DISEASE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P1; TRIAZOLES;

ANIMALIA; PARKINSONIA; RATTUS; RODENTIA;

EID: 62249214963     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2009.02.001     Document Type: Article

References (71)

1. Alfinito P.D., Wang S.P., Manzino L., Rijhsinghani S., Zeevalk G.D., and Sonsalla P.K. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci 23 (2003) 10982-10987
2. Antoniou K., Papadopoulou-Daifoti Z., Hyphantis T., Papathanasiou G., Bekris E., Marselos M., et al. A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacology (Berl) 183 (2005) 154-162
3. Beninger R.J. The role of dopamine in locomotor activity and learning. Brain Res 287 (1983) 173-196
4. Bibbiani F., Oh J.D., Petzer J.P., Castagnoli Jr. N., and Chen J.F. Schwarzschild MA et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 184 (2003) 285-294
5. Birkmayer W., Riederer P., and Youdim B.H. Distinction between benign and malignant type of Parkinson's disease. Clin Neurol Neurosurg 81 (1979) 158-164
6. Calabrese E.J. An assessment of anxiolytic drug screening tests: hormetic dose responses predominate. Crit Rev Toxicol 38 (2008) 489-542
7. Chen J.F., Beilstein M., Xu Y.H., Turner T.J., Moratalla R., Standaert D.G., et al. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience 97 (2000) 195-204
8. Clow A., Jenner P., and Marsden C.D. Changes in dopamine-mediated behaviour during one year's neuroleptic administration. Eur J Pharmacol 57 (1979) 365-375
9. Correa M., and Font L. Is there a major role for adenosine A2A receptors in anxiety?. Front Biosci 13 (2008) 4058-4070
10. Correa M., Wisniecki A., Betz A., Dobson D.R., O'Neill M.F., O'Neill M.J., et al. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 148 (2004) 47-54
11. De la Cruz Lopez F., and Santamaria T.U. The differential haloperidol effect on the immobility response elicited by clamping, grasping, bandaging and inversion in guinea pig, hamster and rat. Behav Brain Res 78 (1996) 195-199
12. De Ryck M., Schallert T., and Teitelbaum P. Morphine versus haloperidol catalepsy in the rat: a behavioral analysis of postural support mechanisms. Brain Res 201 (1980) 143-172
13. El Yacoubi M., Ledent C., Parmentier M., Bertorelli R., Ongini E., Costentin J., et al. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol 134 (2001) 68-77
14. Fastbom J., Pazos A., and Palacios J.M. The distribution of adenosine A1 receptors and 5'-nucleotidase in the brain of some commonly used experimental animals. Neuroscience 22 (1987) 813-826
15. Fastbom J., Pazos A., Probst A., and Palacios J.M. Adenosine A1 receptors in the human brain: a quantitative autoradiographic study. Neuroscience 22 (1987) 827-839
16. Fastbom J., Pazos A., Probst A., and Palacios J.M. Adenosine A1-receptors in human brain: characterization and autoradiographic visualization. Neurosci Lett 65 (1986) 127-132
17. Ferre S., O'Connor W.T., Fuxe K., and Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci 13 (1993) 5402-5406
18. Fischer D.A., Ferger B., and Kuschinsky K. Discrimination of morphine- and haloperidol-induced muscular rigidity and akinesia/catalepsy in simple tests in rats. Behav Brain Res 134 (2002) 317-321
19. Fishman R.H., Feigenbaum J.J., Yanai J., and Klawans H.L. The relative importance of dopamine and norepinephrine in mediating locomotor activity. Prog Neurobiol 20 (1983) 55-88
20. Florio C., Prezioso A., Papaioannou A., and Vertua R. Adenosine A1 receptors modulate anxiety in CD1 mice. Psychopharmacology (Berl) 136 (1998) 311-319
21. Fredholm B.B., Cunha R.A., and Svenningsson P. Pharmacology of adenosine A2A receptors and therapeutic applications. Curr Top Med Chem 3 (2003) 413-426
22. Fredholm B.B., and Svenningsson P. Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities. Neurology 61 (2003) S5-S9
23. Fuxe K., Marcellino D., Rivera A., Diaz-Cabiale Z., Filip M., Gago B., et al. Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res Rev 58 (2008) 415-452
24. Gale C., and Martyn C. Tobacco, coffee, and Parkinson's disease. BMJ 326 (2003) 561-562
25. Golembiowska K., and Dziubina A. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology 47 (2004) 414-426
26. Gottwald M.D., and Aminoff M.J. New frontiers in the pharmacological management of Parkinson's disease. Drugs of Today (Barc) 44 (2008) 531-545
27. Guttmacher L.B., Murphy D.L., and Insel T.R. Pharmacologic models of anxiety. Compr Psychiatry 24 (1983) 312-326
28. Hauber W. Blockade of subthalamic dopamine D1 receptors elicits akinesia in rats. Neuroreport 9 (1998) 4115-4118
29. Hauber W. Involvement of basal ganglia transmitter systems in movement initiation. Prog Neurobiol 56 (1998) 507-540
30. Hauser R.A., Shulman L.M., Trugman J.M., Roberts J.W., Mori A., Ballerini R., et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 23 (2008) 2177-2185
31. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
32. Hurley M.J., Mash D.C., and Jenner P. Adenosine A(2A) receptor mRNA expression in Parkinson's disease. Neurosci Lett 291 (2000) 54-58
33. Ishiwari K., Madson L.J., Farrar A.M., Mingote S.M., Valenta J.P., DiGianvittorio M.D., et al. Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats. Behav Brain Res 178 (2007) 190-199
34. Jankovic J., McDermott M., Carter J., Gauthier S., Goetz C., Golbe L., et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. Neurology. The Parkinson Study Group 40 (1990) 1529-1534
35. Janssen P.A., Niemegeers C.J., and Schellekens K.H. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data?. Arzneimittelforschung 16 (1966) 339-346
36. Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs 14 (2005) 729-738
37. Kafka S.H., and Corbett R. Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. Eur J Pharmacol 295 (1996) 147-154
38. Karcz-Kubicha M., Antoniou K., Terasmaa A., Quarta D., Solinas M., Justinova Z., et al. Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28 (2003) 1281-1291
39. Kase H., Aoyama S., Ichimura M., Ikeda K., Ishii A., Kanda T., et al. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 61 (2003) S97-S100
40. Kliethermes C.L. Anxiety-like behaviors following chronic ethanol exposure. Neurosci Biobehav Rev 28 (2005) 837-850
41. Korchounov A., Schipper H.I., Preobrazhenskaya I.S., Kessler K.R., and Yakhno N.N. Differences in age at onset and familial aggregation between clinical types of idiopathic Parkinson's disease. Mov Disord 19 (2004) 1059-1064
42. Malec D. Haloperidol-induced catalepsy is influenced by adenosine receptor antagonists. Pol J Pharmacol 49 (1997) 323-327
43. Molloy A.G., O'Boyle K.M., Pugh M.T., and Waddington J.L. Locomotor behaviors in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists. Pharmacol Biochem Behav 25 (1986) 249-253
44. Montastruc J.L., Llau M.E., Rascol O., and Senard J.M. Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 8 (1994) 293-306
45. Moo-Puc R.E., Gongora-Alfaro J.L., Alvarez-Cervera F.J., Pineda J.C., Arankowsky-Sandoval G., and Heredia-Lopez F. Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy. Neuropharmacology 45 (2003) 493-503
46. Morelli M., and Pinna A. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neurol Sci 22 (2001) 71-72
47. Nehlig A., Daval J.L., and Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 17 (1992) 139-170
48. Oertel W.H. Parkinson's disease: epidemiology, (differential) diagnosis, therapy, relation to dementia. Arzneimittelforschung 45 (1995) 386-389
49. Olanow C.W. The scientific basis for the current treatment of Parkinson's disease. Annu Rev Med 55 (2004) 41-60
50. Otsuka M., Ichiya Y., Kuwabara Y., Hosokawa S., Sasaki M., Yoshida T., et al. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. J Neurol Sci 136 (1996) 169-173
51. Paulus W., and Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50 (1991) 743-755
52. Pinna A., Fenu S., and Morelli M. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39 (2001) 233-238
53. Pinna A., Pontis S., Borsini F., and Morelli M. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse 61 (2007) 606-614
54. Pinna A., Volpini R., Cristalli G., and Morelli M. New adenosine A2A receptor antagonists: actions on Parkinson's disease models. Eur J Pharmacol 512 (2005) 157-164
55. Rascol O., Payoux P., Ory F., Ferreira J.J., Brefel-Courbon C., and Montastruc J.L. Limitations of current Parkinson's disease therapy. Ann Neurol 53 Suppl 3 (2003) S3,S12 discussion S12-5
56. Salamone J.D., Betz A.J., Ishiwari K., Felsted J., Madson L., Mirante B., et al. Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Front Biosci 13 (2008) 3594-3605
57. Salamone J.D., Ishiwari K., Betz A.J., Farrar A.M., Mingote S.M., Font L., et al. Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism. Parkinsonism Relat Disord 14 Suppl 2 (2008) S130-S134
58. Schiess M.C., Zheng H., Soukup V.M., Bonnen J.G., and Nauta H.J. Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. Parkinsonism Relat Disord 6 (2000) 69-76
59. Schwarzschild M.A., Agnati L., Fuxe K., Chen J.F., and Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 29 (2006) 647-654
60. Simola N., Fenu S., Baraldi P.G., Tabrizi M.A., and Morelli M. Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol 189 (2004) 182-188
61. Sitkovsky M.V., Lukashev D., Apasov S., Kojima H., Koshiba M., Caldwell C., et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22 (2004) 657-682
62. Spiegel J., Hellwig D., Samnick S., Jost W., Mollers M.O., Fassbender K., et al. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. J Neural Transm 114 (2007) 331-335
63. Svenningsson P., Nergardh R., and Fredholm B.B. Regional differences in the ability of caffeine to affect haloperidol-induced striatal c-fos mRNA expression in the rat. Neuropharmacology 37 (1998) 331-337
64. Svenningsson P., Nomikos G.G., Ongini E., and Fredholm B.B. Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience 79 (1997) 753-764
65. Tanganelli S., Sandager Nielsen K., Ferraro L., Antonelli T., Kehr J., Franco R., et al. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease. Parkinsonism Relat Disord 10 (2004) 273-280
66. Thorsell A., Johnson J., and Heilig M. Effect of the adenosine A2a receptor antagonist 3,7-dimethyl-propargylxanthine on anxiety-like and depression-like behavior and alcohol consumption in Wistar Rats. Alcohol Clin Exp Res 31 (2007) 1302-1307
67. Varty G.B., Hodgson R.A., Pond A.J., Grzelak M.E., Parker E.M., and Hunter J.C. The effects of adenosine A(2A) receptor antagonists on haloperidol-induced movement disorders in primates. Psychopharmacology (Berl) 200 3 (2008) 393-401
68. Vingerhoets F.J., Schulzer M., Calne D.B., and Snow B.J. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Ann Neurol 41 (1997) 58-64
69. Vortherms T.A., and Watts V.J. Sensitization of neuronal A2A adenosine receptors after persistent D2 dopamine receptor activation. J Pharmacol Exp Ther 308 (2004) 221-227
70. Wichmann T., and DeLong M.R. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv Neurol 91 (2003) 9-18
71. Wolgin D.L. Forelimb placing and hopping reflexes in haloperidol- and morphine-treated cataleptic rats. Behav Neurosci 99 (1985) 423-435